Hematology

Latest News

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

May 17th 2025

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

May 16th 2025

Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

May 16th 2025

Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com
Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

May 15th 2025

One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

May 6th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

CLL: Data Impact and Sequencing Approach
July 11th 2018

CLL: Data Impact and Sequencing Approach

Clinical Significance of Upfront Ibrutinib in CLL
July 11th 2018

Clinical Significance of Upfront Ibrutinib in CLL

CLL: When to Initiate Frontline Therapy
July 11th 2018

CLL: When to Initiate Frontline Therapy

Identifying Mutational Status in CLL
July 11th 2018

Identifying Mutational Status in CLL

Diagnosing Chronic Lymphocytic Leukemia
July 11th 2018

Diagnosing Chronic Lymphocytic Leukemia

Site Logo
July 11th 2018

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

Kelly Fust, MS Anju Parthan, PhD Xiaoyan Li, PhD Anjali Sharma, MD Xinke Zhang, MS Marco Campioni, PhD Junji Lin, PhD, MS Xuena Wang, PhD Richard Zur, PhD Karynsa Cetin, MPH Melissa Eisen, MD David Chandler, PhD
This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR
July 10th 2018

Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR

Laura Joszt, MA
Ixazomib taken twice weekly with lenalidomide and dexamethasone resulted in high overall response rate (ORR) and a durable response among patients with newly diagnosed multiple myeloma (MM).
Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM
July 6th 2018

Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM

Laura Joszt, MA
Research presented at the 2018 American Society of Clinical Oncology Annual Meeting identified predictors of long-term survival and health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma (MM).
Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced
July 5th 2018

Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced

Laura Joszt, MA
A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.
Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML
June 30th 2018

Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML

Laura Joszt, MA
Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously untreated acute myeloid leukemia (AML), the FDA has granted the Pfizer drug a Priority Review.
Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy
June 27th 2018

Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy

Laura Joszt, MA
Cancer cells can take advantage of the BCL-2 protein to survive chemotherapy, but a drug that suppresses BCL-2 may have promise in patients with leukemia who produce too much of the protein.
Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas
June 22nd 2018

Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas

Laura Joszt, MA
Patients with myelofibrosis who were treated with Janus-kinase (JAK) 1/2 inhibitors have an increased risk for developing B-cell lymphoma. However, researchers believe there is a pre-existing B-cell clone that patients can be tested for before treatment.
Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy
June 19th 2018

Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy

Laura Joszt, MA
An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16th 2018

Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15th 2018

Gene Editing Could Reduce Toxicity of CAR T Treatment in AML

Laura Joszt, MA
A new approach using gene editing technology could allow chimeric antigen receptor (CAR) T cells to target CD33 in patients with acute myeloid leukemia (AML) but prevent the cells from attacking healthy stem cells, too.
Translocated Bacteria Can Lead to a Precursor Condition of Leukemia
June 12th 2018

Translocated Bacteria Can Lead to a Precursor Condition of Leukemia

Laura Joszt, MA
A stem cell mutation that leads to bacterial translocation may help identify patients at risk of developing leukemia.
Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma
June 6th 2018

Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
The interim analysis of the phase 3 A.R.R.O.W. trial found that once-weekly carfilzomib at 70 mg/m2 had superior progression-free survival and overall response rates compared with twice-weekly carfilzomib at 27 mg/m2.
Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations
June 4th 2018

Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations

Laura Joszt, MA
An experimental drug for patients with acute myeloid leukemia (AML) with mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) was found to be safe with durable remissions.
Analyzing Worries in Leukemia and Economic Burden in Lymphoma
June 2nd 2018

Analyzing Worries in Leukemia and Economic Burden in Lymphoma

Laura Joszt, MA
Two abstracts presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting highlighted patient experiences in blood cancers. One highlighted the worries of patients with acute myeloid leukemia, and the other analyzed economic burdens and resource utilization for patients with non-Hodgkin lymphoma.
Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma
May 31st 2018

Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma

Laura Joszt, MA
Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.
Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments
May 26th 2018

Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments

Laura Joszt, MA
A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.
Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy
May 24th 2018

Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy

Laura Joszt, MA
Analysis of patient-reported outcomes found patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with inotuzumab ozogamicin reported better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Site Logo
May 18th 2018

Study Reports Highest Survival Rates for Children, Young Adults With Certain T-Cell Leukemias

Laura Joszt, MA
A phase III randomized trial, with results being presented in June at the American Society of Clinical Oncology Annual Meeting, found the addition of nelarabine to standard chemotherapy regimen in patients with T-cell malignancies can improve disease-free survival rates.
FDA Approves Epoetin Alfa Biosimilar for Anemia
May 15th 2018

FDA Approves Epoetin Alfa Biosimilar for Anemia

Jaime Rosenberg
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating agent approved in the United States.
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 9th 2018

CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia

Samantha DiGrande
A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
Daratumumab Approved as Frontline Treatment in Newly Diagnosed Multiple Myeloma
May 8th 2018

Daratumumab Approved as Frontline Treatment in Newly Diagnosed Multiple Myeloma

Laura Joszt, MA
The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
This Week in Managed Care: May 4, 2018
May 4th 2018

This Week in Managed Care: May 4, 2018

This week, the top managed care stories included a report that insurance coverage gains are reversing; a deal to lower the cost of Praluent for Express Scripts members; findings that synthetic opioids are playing a bigger role in overdose deaths.
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018

FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma

Jaime Rosenberg
Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits
May 2nd 2018

What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits

AJMC Staff
The chimeric antigen receptor T-cell therapy tisagenlecleucel has been approved for a second type of blood cancer; the National Institutes of Health has started recruiting individuals for a database that will include data on more than 1 million people; Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility.
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 1st 2018

Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education

Chimeric antigen receptor (CAR) T-cell treatments are still new enough that there are still unknown regarding long-term side effects, which is something patients need to understand before they undergo treatment, said Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
<1
...
161718192021222324
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo